Supplementary Table 1. Univariate analysis for relapse, OS and CRFS

	Relapse		os		CRFS	
Patient and Graft Characteristics	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Sex Male Female	Ref. 0.7 (0.4-1.1)	0.11	Ref. 1.1 (0.8-1.5)	0.63	Ref. 1 (0.7-1.4)	1.00
D/R gender combination Female to Male Other	Ref. 1.1 (0.6-1.9)	0.85	Ref. 1.4 (0.9-2.2)	0.14	Ref. 1.4 (0.9-2.1)	0.15
Age (years) < 40 (n =) >40 (n =)	Ref. 1 (0.5-1.7)	0.87	Ref. 1.5 (0.9-2.4)	0.09	Ref. 1.4 (0.9-2.1)	0.16
Donor Related donor Non-related donor	Ref. 0.8 (0.5-1.3)	0.37	Ref. 1.2 (0.9-1.6)	0.33	Ref. 1.2 (0.9-1.6)	0.32
HLA compatibility Identical Non-identical	Ref. 0.8 (0.5-1.4)	0.39	Ref. 1.2 (0.9-1.7)	0.24	Ref. 1.2 (0.8-1.6)	0.34
Diagnosis Acute myeloid leukemia Myelodisplastic syndrome	Ref. 0.7 (0.4-1.2)	0.19	Ref. 1 (0.7-1.4)	0.96	Ref. 0.9 (0.7-1.3)	0.68
Transplant year	Ref. 1.1 (1-1.2)	0.03	Ref. 1 (1-1.1)	0.85	Ref. 1.0 (1-1.1)	0.92
HCT-CI 0 1-2 ≥3	Ref. 0.6 (0.3-1.2) 1 (0.6-1.6)		Ref. 1 (0.6-1.6) 1.9 (1.3-2.9)		Ref. 0.8 (0.5-1.3) 1.5 (1-2.3)	0.001
HCT-CI/age 0 1-2 3-4 ≥5	Ref. 1 (0.3-2.8) 0.9 (0.3-2.7) 1.2 (0.4-3.4)	0.90	Ref. 2.1 (0.6-6.6) 3.2 (1-10.1) 5 (1.6-16.1)	< 0.001	Ref. 1.1 (0.5-2.5) 1.6 (0.7-3.6) 2.3 (1-5.2)	0.001
Conditioning regimen TBI based Chemo based	Ref. 0.9 (0.5-1.4)	0.56	Ref. 1.3 (0.9-1.8)	0.20	Ref. 1.2 (0.9-1.7)	0.23
CD34+ x 10⁶/kg dose < 7.6x10 ⁶ /kg > 7.6x10 ⁶ /kg	Ref. 1.2 (0.7-1.8)	0.84	Ref. 0.9 (0.7-1.3)	0.60	Ref. 0.9 (0.7-1.3)	0.52

CD34+ selection method						
Clinimacs ®	Ref.	0.10	Ref.	0.90	Ref.	0.80
OTHER	0.7 (0.4-1.1)		1 (0.7-1.4)		1 (0.7-1.3)	

Abbreviations: NRM, non-relapse mortality; OS, overall survival, CRFS Chronic GVHD-Free, Relapse-Free Survival; D/R, donor/recipient; HCT-CI, Hematopoietic Cell Transplantation Comorbidity Index.